Final overall survival results and effect of prolonged (≥1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial

Breast Cancer Research and Treatment

Volumn 130, Issue 1, 2011, Pages 133-143

  Smith, Ian ^a,b   Pierga, Jean Yves ^c   Biganzoli, Laura ^d   Cortes Funes, Hernan ^e   Thomssen, Christoph ^f   Saracchini, Silvana ^g   Nisenbaum, Bella ^h   Pelaez, Ignacio ⁱ   Duenne, Anja Alexandra ^j   Pritchard, Kathleen I ^k  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c INSTITUT CURIE   (France)

^d Tuscany Cancer Institute   (Italy)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^g Santa Maria Degli Angeli   (Italy)

^h MEIR MEDICAL CENTER   (Israel)

ⁱ HOSPITAL DE CABUEÑES   (Spain)

^j F HOFFMANN LA ROCHE LTD   (Switzerland)

^k DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

more..

Author keywords

Angiogenesis; Bevacizumab; Duration; First line therapy; Maintenance; Metastatic breast cancer

Indexed keywords

BEVACIZUMAB; DOCETAXEL; PACLITAXEL;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEINURIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM METASTASIS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 82455199216     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1695-8     Document Type: Article

References (18)

1. Gray R, Bhattacharya S, Bowden C et al (2009) Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 27:4966-4972
2. Miles DW, Chan A, Dirix LY et al (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:3239-3247
3. Robert NJ, Diéras V, Glaspy J et al (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29:1252-1260
4. Brufsky A, Bondarenko IN, Smirnov V et al (2009) RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. Cancer Res 69(suppl):495s (Abstract 42)
5. Smith IE, Pierga JY, Biganzoli L et al (2011) First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients. Ann Oncol 22:595-602
6. Schneider BP, Wang M, Radovich M et al (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26:4672-4678
7. Cameron D (2008) Bevacizumab in the first-line treatment of metastatic breast cancer. Eur J Cancer (Suppl 6):21-28
8. Thomssen C, Pierga J-Y, Pritchard KI et al (2009) First-line bevacizumab (Bev) combination therapy in triple-negative (TN) locally recurrent/metastatic breast cancer (LR/MBC): subpopulation analysis of study MO19391 in>2000 patients (pts). Cancer Res 69 (Suppl 24):854s (Abstract 6093)
9. Biganzoli L, Di Vincenzo E, Jiang Z et al (2011) First-line bevacizumab-containing therapy for breast cancer: results in patients aged ≥70 years treated in the ATHENA study. Ann Oncol. doi:10.1093/annonc/mdr043
10. O'Shaughnessy J, Romieu G, Dieras V et al (2010) Meta-analysis of patients with triple-negative breast cancer (TNBC) from three randomized trials of first-line bevacizumab (BV) and chemotherapy treatment for metastatic breast cancer (MBC). Cancer Res 70 (Suppl 24):452s (Abstract P6-12-03)
11. Brufsky A, Valero V, Tiangco B et al (2011) Impact of bevacizumab (BEV) on efficacy of second-line chemotherapy (CT) for triple-negative breast cancer (TNBC): analysis of RIBBON-2. J Clin Oncol 29(suppl):1010 (abstract)
12. Burger RA, Brady MF, Bookman MA et al. (2010) Safety and subgroup efficacy analyses in GOG218, a phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) or fallopian tube cancer (FTC): a Gynecologic Oncology Group study. Ann Oncol 21(Suppl 8):viii307 (Abstract 978PD)
13. Aogi K, Masuda N, Ohno S et al (2011) First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study. Breast Cancer Res Treat. doi:10.1007/s10549-011-1685-x
14. Traina TA, Rugo HS, Caravelli JF et al (2010) Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. J Clin Oncol 28:628-633
15. Yardley DA, Burris HA 3rd, Clark BL et al (2011) Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Breast Cancer 11:146-152
16. Bidard FC, Mathiot C, Degeorges A et al (2010) Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol 21:1765-1771
17. Etienne-Grimaldi MC, Formento P, Degeorges A et al (2011) Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients. Br J Clin Pharmacol 71:921-928
18. Miles DW, de Haas SL, Dirix L et al. (2010) Plasma biomarker analyses in the AVADO phase III randomized study of first-line bevacizumab + docetaxel in patients with human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer. Cancer Res 70 (Suppl 24):235s (Abstract P2-16-04)